Skip to main content

Table 1 Baseline characteristics of adult patients receiving apixaban before and after propensity score matching

From: Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

 

Before propensity score (PS) matching

After propensity score (PS) matching

 

Overall (N = 722)

BMI < 40 (N = 595)

BMI ≥ 40 (N = 127)

P-value

Overall (N = 254)

BMI < 40 (N = 127)

BMI ≥ 40 (N = 127)

P-value

Age (Years), Mean (SD)

69.9 (11.39)

70.2 (11.56)

68.3 (10.46)

0.0212^

68.3 (10.31)

68.3 (10.20)

68.3 (10.46)

0.9806*

Gender – Male, n (%)

307 (42.5)

291 (48.9)

16 (12.6)

<.0001^^

32 (12.6)

16 (12.6)

16 (12.6)

 0.9999^^

Weight (kg), Mean (SD)

83.4 (18.90)

78.1 (14.33)

108.4 (17.72)

<.0001*

91.8 (22.59)

75.2 (12.47)

108.4 (17.72)

<.0001*

Body Mass Index (BMI), Median (Q1, Q3)

32.1 (27.33, 37.86)

30.5 (26.63, 34.57)

43.9 (41.71, 47.74)

<.0001*

39.8 (32.45, 43.86)

32.5 (27.18, 35.41)

43.9 (41.71, 47.74)

<.0001*

Alanine aminotransferase (ALT), Median (Q1, Q3)

21.0 (14.00, 31.00)

21.0 (14.00, 31.00)

19.0 (13.00, 25.00)

0.0551^

19.5 (13.00, 28.00)

20.0 (13.00, 29.50)

19.0 (13.00, 25.00)

0.7210^

Aspartate aminotransferase (AST), Median (Q1, Q3)

22.0 (17.00, 29.00)

22.0 (17.00, 29.00)

21.0 (16.00, 28.00)

0.1182^

21.0 (16.00, 28.00)

21.5 (15.50, 27.00)

21.0 (16.00, 28.00)

0.9873^

Estimated glomerular filtration rate (eGFR), Median (Q1,Q3)

83.0 (69.00, 97.00)

83.0 (69.50, 98.00)

80.0 (63.00, 92.00)

0.0229^

81.0 (67.00, 94.00)

83.0 (71.00, 97.00)

80.0 (63.00, 92.00)

0.1693*

Serum creatinine (mmol/l), Median (Q1,Q3)

73.0 (64.00, 90.00)

73.5 (64.00, 90.00)

70.0 (63.00, 85.00)

0.1956^

69.0 (62.00, 82.00)

69.0 (61.00, 77.00)

70.0 (63.00, 85.00)

0.1698^

Blood Urea Nitrogen (BUN) (mmol/l), Median (Q1,Q3)

5.6 (4.30, 7.30)

5.6 (4.30, 7.20)

5.7 (4.10, 7.85)

0.8249^

5.3 (4.00, 7.30)

5.1 (4.00, 6.60)

5.7 (4.10, 7.85)

0.1059^

Platelets count (10^9/L), Median (Q1, Q3)

245.0 (203.00, 312.00)

244.5 (203.00, 309.50)

255.0 (203.00, 333.00)

0.2074^

261.0 (205.50, 335.00)

264.0 (209.00, 335.00)

255.0 (203.00, 333.00)

0.6115^

Hematocrit (Hct), Median (Q1, Q3)

0.4 (0.35, 0.44)

0.4 (0.35, 0.44)

0.4 (0.37, 0.44)

0.4713^

0.4 (0.35, 0.43)

0.4 (0.35, 0.42)

0.4 (0.37, 0.44)

0.0366^

Total WBC (10^9/L), Median (Q1, Q3)

7.8 (6.10, 10.00)

7.7 (6.10, 10.00)

8.1 (6.40, 9.94)

0.4107^

8.0 (6.17, 10.05)

7.9 (6.10, 10.10)

8.1 (6.40, 9.94)

0.6404^

International normalized ratio (INR), Median (Q1,Q3)

1.1 (1.04, 1.20)

1.1 (1.05, 1.22)

1.1 (1.02, 1.14)

0.0010^

1.1 (1.03, 1.15)

1.1 (1.04, 1.20)

1.1 (1.02, 1.14)

0.2394^

Activated partial thromboplastin time (aPTT) (Seconds), Median (Q1, Q3)

29.9 (27.20, 34.40)

30.1 (27.45, 34.75)

28.8 (26.40, 33.10)

0.0058^

29.4 (26.80, 33.90)

29.8 (27.40, 34.40)

28.8 (26.40, 33.10)

0.0453^

Total bilirubin (μmol/L), Median (Q1, Q3)

10.7 (8.10, 14.80)

10.7 (8.10, 15.00)

10.7 (7.80, 13.30)

0.3140^

9.8 (7.40, 12.90)

9.1 (7.10, 12.70)

10.7 (7.80, 13.30)

0.0805^

Albumin (gm/L), Median (Q1, Q3)

37.0 (33.00, 40.00)

37.0 (32.00, 40.00)

36.0 (33.00, 39.00)

0.6269^

37.0 (33.00, 39.00)

37.0 (33.00, 40.00)

36.0 (33.00, 39.00)

0.2868^

Fibrinogen Level (gm/l), Median (Q1,Q3)

3.9 (2.59, 5.16)

3.9 (2.29, 5.00)

5.5 (4.63, 6.18)

0.0494*

4.8 (1.64)

4.2 (1.96)

5.4 (1.02)

0.3234*

D-dimer Level (mg/l), Median (Q1,Q3)

1.1 (0.47, 2.92)

1.2 (0.50, 3.08)

1.0 (0.47, 2.74)

0.7596^

1.1 (0.46, 2.86)

1.1 (0.42, 3.70)

1.0 (0.47, 2.74)

0.9782^

Blood sugar level (mmol/L), Median (Q1, Q3)

7.8 (5.90, 11.40)

7.7 (5.90, 11.20)

8.8 (6.10, 11.80)

0.1628^

8.7 (6.00, 12.50)

8.4 (5.90, 13.20)

8.8 (6.10, 11.80)

0.7573^

CHA2DS2-VASc Score, Median (Q1, Q3)

4.0 (3.00, 5.00)

4.0 (3.00, 5.00)

4.0 (3.00, 5.00)

0.5234^

4.0 (3.00, 5.00)

4.0 (3.00, 5.00)

4.0 (3.00, 5.00)

0.8711^

HAS-BLED Score, Median (Q1, Q3)

2.0 (1.00, 3.00)

2.0 (1.00, 3.00)

2.0 (1.00, 3.00)

0.0993^

2.0 (1.00, 2.00)

2.0 (1.00, 2.00)

2.0 (1.00, 3.00)

0.5930^

History of Major Bleeding, n (%)

4 (0.6)

3 (0.5)

1 (0.8)

0.6963**

3 (1.2)

2 (1.6)

1 (0.8)

0.5614**

History of Bariatric Surgery, n (%)

1 (0.1)

0 (0.0)

1 (0.8)

0.0303**

1 (0.4)

0 (0.0)

1 (0.8)

0.3164**

Concomitant Aspirin use, n (%)

257 (36.0)

218 (37.0)

39 (31.5)

0.2412^^

82 (33.1)

43 (34.7)

39 (31.5)

0.5893^^

Concomitant Clopidogrel use, n (%)

93 (13.0)

82 (13.9)

11 (8.8)

0.1223^^

29 (11.7)

18 (14.5)

11 (8.8)

0.1598^^

Concomitant Ticagrelor use, n (%)

2 (0.3)

2 (0.3)

0 (0.0)

0.5141**

0 (0)

0 (0)

0 (0)

NA

Concomitant use of GI prophylaxis (i.e., PPI or H2A), n (%)

602 (83.4)

497 (83.5)

105 (82.7)

0.81

214 (84.3)

108 (85.0)

106 (83.4)

0.7509^^

Comorbidity

Aortic Stenosis (AS), n (%)

32 (4.4)

27 (4.5)

5 (3.9)

0.7652^^

10 (3.9)

5 (3.9)

5 (3.9)

> 0.9999^^

Mitral Stenosis (MS), n (%)

28 (3.9)

23 (3.9)

5 (3.9)

0.9698**

10 (3.9)

5 (3.9)

5 (3.9)

> 0.9999^^

Chronic obstructive pulmonary disease (COPD), n (%)

42 (5.8)

30 (5.0)

12 (9.4)

0.0541^^

22 (8.66)

10 (7.87)

12 (9.45)

0.6555^^

Heart Failure, n (%)

315 (43.6)

253 (42.5)

62 (48.8)

0.1939^^

111 (43.7)

49 (38.6)

62 (48.8)

0.1001^^

Hypertension, n (%)

606 (83.9)

490 (82.4)

116 (91.3)

0.0123^^

228 (89.7)

112 (88.2)

116 (91.3)

0.4077^^

Diabetes mellitus, n (%)

490 (67.9)

396 (66.6)

94 (74.0)

0.1021^^

179 (70.5)

85 (66.9)

94 (74.0)

0.2157^^

Dyslipidemia, n (%)

395 (54.7)

324 (54.5)

71 (55.9)

0.7654^^

147 (57.8)

76 (59.8)

71 (55.9)

0.5252^^

Hypothyroidism, n (%)

120 (16.6)

101 (17.0)

19 (15.0)

0.5799^^

44 (17.3)

25 (19.7)

19 (14.9)

0.3198^^

Hyperthyroidism, n (%)

9 (1.2)

8 (1.3)

1 (0.8)

0.6074**

3 (1.18)

2 (1.57)

1 (0.79)

0.5614

Ischemic heart disease (IHD), n (%)

190 (26.3)

165 (27.7)

25 (19.7)

0.0616^^

54 (21.3)

29 (22.8)

25 (19.7)

0.5396^^

Chronic kidney disease (CKD), n (%)

85 (11.8)

72 (12.1)

13 (10.2)

0.5539^^

27 (10.6)

14 (11.0)

13 (10.2)

0.8387^^

Cancer, n (%)

39 (5.4)

33 (5.5)

6 (4.7)

0.7099^^

13 (5.1)

7 (5.5)

6 (4.7)

0.7758^^

Venous Thromboembolism, n (%)

45 (6.2)

39 (6.6)

6 (4.7)

0.4386^^

14 (5.5)

8 (6.3)

6 (4.7)

0.5824^^

Vascular Disease, n (%)

9 (1.2)

6 (1.0)

3 (2.4)

0.2119**

4 (1.6)

1 (0.8)

3 (2.4)

0.3135**

Liver disease (any type), n (%)

34 (4.7)

29 (4.9)

5 (3.9)

0.6509^^

9 (3.5)

4 (3.1)

5 (3.9)

0.7343**

Stroke, n (%)

136 (18.8)

121 (20.3)

15 (11.8)

0.0257^^

41 (16.1)

26 (20.5)

15 (11.8)

0.0607^^

  1. *T Test / ^ Wilcoxon rank sum test is used to calculate the P-value
  2. ^^ Chi square/ ** Fisher’s Exact teat is used to calculate P-value